Injectable carbon compositions in stable aqueous suspension; method for preparing them and method of presurgical marking in the investigation of nonpalpable mammary pathologies by applying said compositions; use of activated carbon of selective granulometry for the preparation of said compositions

Abstract

Injectable activated carbon suspensions are proposed for the presurgical marking of nonpalpable mammary pathologies for the purpose of achieving better diagnosis and treatment.

Description

1. The present invention relates to “carbon marking” of the breast for the purpose of localizing and delimiting histologically anomalous zones revealed by other techniques, such as echographic or radiographic, thus making possible more convenient and safer surgical access from the standpoint of precision of diagnosis and treatment and of aesthetic considerations with the mammary tissues undergoing surgery.

2. Among the presurgical techniques of delimitation of nonpalpable mammary lesions, carbon marking forms part of the set of techniques whose application requires operating on the breast in minimally invasive form, for example, through the insertion of a needle to discharge the carbon in the zone investigated under radiographic or echographic monitoring.

3. Other techniques of this group include marking using wires bent at one of their ends (hooks or harpoons) which are inserted in the mammary tissue using a tubular piece for guiding and positioning in relation to the target (lesion) under radiographic monitoring. Another technique of said group involves the injection of organic dye solutions, such as methylene blue or toluidine blue, for purposes of demarcating the zone to be studied.

4. No method of presurgical demarcation of nonpalpable mammary lesions, whether noninvasive or minimally invasive, is free of defects: the noninvasive methods, which basically involve the use of measurements from reference points (the nipple, for example) and marking of the skin, raise the possibility of unreliable markings and the ultimate results entail the risk of either overly wide or incomplete exeresis, with the possibility in both cases of mammary disfiguration.

5. In the use of minimally invasive techniques, the risks are in relation to the nature of the instrument used. In the case of the hook, for examples although it is more precise than the previous technique, the instrument can possibly be displaced, with the formation of visible lesions, such as localized hemorrhages and hematomas.

6. Marking employing solutions of organic dyes like methylene blue or toluidine blue entails the need for rapid continuation of the diagnostic-therapeutic procedure, in view of the possibility of migration, diffusion and degradation of this type of dye.

7. The use of carbon in turn requires careful choice of the preparation, as to its granulometry (particle size) and needle gage, in combination with a degree of skill in handling the injection device. All of these measures are aimed at preventing obstruction of the needle and promoting release of a continuous flow without interruptions, even in the course of extraction of the needle.

8. With respect to the latter technique (carbon marking), injectable suspensions of 4% carbon in an aqueous medium are used and they are administered by injection with needles in the order of 20G.

9. This technique has met with quick acceptance thanks to its reduced cost and the overcoming of disadvantages usually present with other techniques, such as lack of precision, displacement of the marking instrument and rapid degradation, among other things. The use of carbon as presurgical marker, on the other hand, offers among its advantages prolonged permanence in the zone marked, with color and limits well differentiated and, not being radiopaque, neither the radiology of the specimen nor the histopathological examination of same being altered. Furthermore, suspensions of carbon particles in an aqueous medium are involved, which is physiologically appropriate.

10. The different techniques of presurgical localization of nonpalpable mammary lesions are described in the specialized bibliography (1) (2).

11. It is clear from what has been summarized in the foregoing text that presurgical mammary marking with aqueous carbon solutions is considered an extremely useful technique from the operational as well as economical standpoint, in spite of its possible limitations, such as obstruction of needles because of inadequate particle size and collapse or discontinuity of the discharge flow or stream.

12. This invention makes it possible to resolve the negative aspects mentioned by providing activated carbon suspensions of adequate particle size within precise limits, resulting in an operational improvement of the technique, being less difficult, more reliable and precise for the physician and more comfortable for the patient.

THE INVENTION

13. The main object of the present invention consists of injectable activated carbon solutions for the presurgical marking of mammary lesions, which comprise, in aqueous suspension, ground activated carbon having, all together, particles smaller than 50&mgr; in size and preferably between 2&mgr; and 6&mgr;. Said compositions flow freely and without the formation of obstructing aggregates in the needles during their application.

14. The process of preparation of activated carbon of the aforementioned granulometry is also the object of the invention, useful for formulating said injectable compositions, preferably by grinding the activated carbon in a cylindrical rod mill, whose surface has a sufficient hardness for obtaining the effect desired, like, for example, those of zirconia (ZrO2).

DETAILED DESCRIPTION OF THE INVENTION

15. Innovations in the art of preparing compositions for the presurgical marking of mammary lesions are combined in this invention, using aqueous suspensions of activated carbon as marker for identifying and delimiting the zone to be operated on, namely:

16. the selection of an optimum particle size of carbon for formulating compositions that flow freely and without the formation of obstructing aggregates in the needles used during their application;

17. the selection and relationship of the means making it possible to obtain and use activated carbon of that optimal particle size from the functional standpoint.

18. Said optimal particle size is clearly attainable according to this invention by processing the activated carbon preferably in roll (or rod) mills whose operating surface has sufficient hardness. Included within said range, among others, is zirconium oxide—zirconia (ZrO2)—with a hardness of 1160 units on the Knoop Scale, which is preferably applicable as a component of the body or surface of said rods. The use of this type of mill is a preferred aspect of the present invention. Even more preferable is the combination of the grinding of activated carbon using said rods of zirconia (or coated with zirconia) in chambers or drums whose interior surface is polyurethane. With the combination of these two factors, grinding and abrasive surfaces of zirconia and polyurethane coating of the grinding chamber, the profile of distribution of particles sizes shown on the graph of FIG. 1 of injectable compositions for the presurgical marking of mammary lesions is obtained.

19. Other objects of the invention are: the methods for marking histologically abnormal mammary zones by injecting effective quantities of activated carbon of particle size less than 50&mgr;, and preferably between 2&mgr; and 6&mgr;, in aqueous suspension and dosage form used in said method.

DESCRIPTION OF THE FIGURES

20. FIG. 1 corresponds to the graph of the profile of distribution of particle sizes of the injectable composition obtained in this invention, which was determined by using a Series 2600 Malvern Laser unit by the Laser Radiation Scattering method.

21. It is observed that the average value of 4.46&mgr; (D[v,0.5]) comes within the preferred range of 2&mgr; to 6&mgr;, there being no particles with values higher than 50&mgr;.

22. FIG. 2 corresponds to a graph similar to that of FIG. 1 of the injectable composition obtained without having undergone the grinding process, which was determined by using the same equipment described above.

23. It is observed that the average value of 31.85 &mgr; (D[v,0.5]) is outside the preferred range of 2&mgr; to 6&mgr;, particles existing with values higher than 50&mgr; (and even exceeding 300&mgr;).

24. In the following example included by way of illustration, a preferred embodiment is described for obtaining activated carbon of granulometry conforming to the present invention.

DESCRIPTION OF THE MANUFACTURING PROCESS

25. 1. In a stainless steel container of 5-lt capacity, equipped with means of stirring, place 1.2 lt of distilled water prefiltered through a membrane of 0.45&mgr; and depyrogenating plate.

26. 2. Connect a helical agitator and add sodium chloride. Stir until dissolving it completely.

27. 3. Add the surface-active agent and stir until dissolving it completely.

28. 4. Add the activated carbon and stir until dispersing it completely.

29. 5. Transfer the carbon suspension formed to an appropriate mill.

30. 6. Grind for approximately 30 hours.

31. 7. Place the ground suspension in a sterile glass vessel of 9-lt capacity and fill to 5 lt with distilled water filter through a 0.45&mgr; membrane and depyrogenating plate.

32. 8. Stir for 15 minutes.

33. 9. Fractionate in Class II neutral glass vial flasks to a proper volume.

34. 10. Plug the flasks with butyl stoppers and aluminum auxiliary cover.

35. 11. Sterilize in autoclave at 121° C. for 20 minutes.

Claims

1. Injectable activated carbon compositions, for application in presurgical marking of mammary lesions, characterized in that they comprise, in aqueous suspension, activated carbon ground and graded to a granulometry with particles not exceeding 50&mgr;, in free-flowing aqueous suspension and without formation of obstructing deposits during their discharge.

2. Compositions in accordance with

claim 1, characterized in that the aqueous medium comprises 0.7 to 1.5% p/v of sodium chloride and 4.0% p/v of activated carbon of said granulometry.

3. Compositions in accordance with

claim 1, characterized in that the ground activated carbon is activated carbon ground in rod mills of zirconium oxide or the like and in grinding chambers coated with polyurethane for at least 30 hours.

4. Compositions in accordance with

claims 1 to

3, characterized in that they comprise 0.3-1.0% p/v of a surface-active agent.

5. Dosage forms for application in presurgical marking of mammary lesions, characterized in that they include proportioned quantities of the composition of

claim 1 in sterile units.

6. Process for preparing activated carbon of selective granulometry, for formation of the compositions of

claim 1, characterized in that it consists of grinding charges of activated carbon in a cylindrical rod mill, in a grinding chamber coated with a nonabrasive lining, for a period in the order of 25 to 60 hours.

7. Process in accordance with

claim 1, characterized in that said rods are made of zirconium oxide or the like and the coating is polyurethane.

8. Process in accordance with

claim 1, characterized in that the grinding time is in the order of 30 hours.

9. Use of activated carbon having a profile of distribution of particle sizes in the order of 2&mgr; to 6&mgr; and no particle greater than 50&mgr;, originating from the grinding of activated carbon in accordance with the process of

claim 6, characterized in that it consists of preparation of the injectable compositions of

claim 1 and the dosage forms of

claim 5 respectively.

10. Method for marking histologically anomalous zones of the breast, characterized in that it consists of injecting effective quantities of the composition of

claim 1.